The U.S. Food and Drug Administration has approved SpringWorks Therapeutics Inc.'s Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment.
Nov 30, 2023
0
0
It's one of those days. On the drive home from work, the car in the next lane cuts you off. You slam on the brakes, lay on the horn, and yell choice words at the offending driver. When you walk into your house half an hour ...
Nov 29, 2023
0
28
Based on results from the CheckMate743 trial, the dual regimen of ipilimumab and nivolumab is the standard of care for the treatment of unresectable pleural mesothelioma. However, research published today in the Journal of ...
Nov 28, 2023
0
0
The strangely named hedgehog pathway that's crucial to bone growth has emerged as a key in the fight to treat the bone cancer osteosarcoma.
Nov 28, 2023
0
1
For patients with advanced or metastatic non-small cell lung cancer (NSCLC) and limited performance status, an immune checkpoint inhibitor drug called durvalumab is safe and may benefit overall survival, according to a new ...
Nov 21, 2023
0
37
With the rapid development in computing power over the past few decades, machine-learning (ML) techniques have become popular in medical settings as a way to predict survival rates and life expectancies among patients diagnosed ...
Nov 20, 2023
0
0
Queen Mary University of London researchers have discovered a new immune mechanism in osteocytes, the most common type of bone cell, that could lead to new drugs for breast and prostate cancer.
Nov 17, 2023
0
35
Extracorporeal membrane oxygenation (ECMO) is a widely used advanced life support procedure that provides cardiac and respiratory support to critically ill patients. ECMO use has been increasing exponentially over the last ...
Nov 16, 2023
0
0
After 40 years of treating metastatic bladder cancer with chemotherapy as a primary treatment, scientists now present a new approach using immunotherapy combinations. The results of two studies have been presented at the ...
Nov 16, 2023
0
1
For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), osimertinib with chemotherapy leads to significantly longer progression-free survival (PFS) compared with osimertinib alone, according to a study ...
Nov 16, 2023
0
1
